上海凱寶(300039.SZ):“痰熱清對慢性阻塞性肺病急性加重期痰熱雍肺證患者腸道微生物多樣性的影響”項目獲得2021年中國民族醫藥協會科學技術進步獎
格隆匯12月27日丨上海凱寶(300039.SZ)公佈,公司於近日獲悉,公司產品“痰熱清對慢性阻塞性肺病急性加重期痰熱雍肺證患者腸道微生物多樣性的影響”項目(項目編號:2021-MZYY-166),獲得2021年中國民族醫藥協會科學技術進步獎一等獎。
公司堅持以企業為主體、市場為導向、產學研相結合的發展道路,重視研發投入及科技成果的轉化。公司主營產品痰熱清注射液/痰熱清膠囊已經在臨牀上呼吸道感染領域應用多年,且療效顯著,自上市以來,公司積極推進主營產品二次開發,開展痰熱清注射液治療慢性阻塞性肺疾病急性加重住院患者的觀察性療效比較研究、痰熱清膠囊聯合治療慢性阻塞性肺病的臨牀療效及其機制研究。2021年6月,公司痰熱清膠囊增加“慢性阻塞性肺病急性發作期輕度”功能主治的申請獲得了《藥物臨牀試驗批准通知書》,同意進行臨牀試驗,為公司後續擴大產品的臨牀應用範圍奠定了基礎。
本獎項的獲得,是對公司產品痰熱清注射液/痰熱清膠囊臨牀價值、創新能力等方面的充分肯定,豐富了痰熱清注射液/痰熱清膠囊的循證醫學證據,為公司產品臨牀數據體系提供了真實可靠的證據鏈;通過明確痰熱清膠囊治療急性加重期慢性阻塞性肺疾病(AECOPD)的臨牀療效和安全性,有助於推進痰熱清膠囊説明書增加新適應症的後續工作,為其臨牀廣泛應用提供依據。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.